ELTX Elicio: רווח נקי למניה ב-12 החודשים האחרונים

Elicio (ELTX) - לוגו תאגידי

The future of Elicio Therapeutics (ELTX) relies on the success of new antitumor drugs and the protection of intellectual property rights. The business is currently in a state of financial deficit, spending capital on research without regular income. The strategy is based on expanding the application of Amphiphile vaccines to capture market share. This price chart reflects the EPS (TTM) dynamics, which currently stands at 46.80.

ELTX - רווח נקי למניה (EPS TTM) elicio.com בטווח 23.11.2025 - 18.11.2026

ELTX (Elicio Therapeutics, Inc.): פילוחים אנליטיים ודוחות לפי אינדיקטורים

- מחיר ותחזית קונצנזוס למחירים:
ניתוח ראשוני של החברה:ELTX, Elicio Therapeutics, Inc.
מוצר עיקרי של elicio.com

This indicator measures the dynamics of net income per share, reflecting the rate of change in business profitability. By analyzing the EPS YoY TTM growth efficiency metric, an investor assesses the issuer's ability to generate profit relative to the previous year. The calculation is based on a comparison of a rolling 12-month window, which eliminates seasonal distortions. For the biotech company Elicio Therapeutics (ELTX), this metric is critical during the transition from R&D expenditures to the commercialization of the AMP platform.